HER-2 targeted treatment of osteosarcoma: The challenges of developing targeted therapy and prognostic factors for rare malignancies

David S. Geller, Richard Gorlick

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Importance of the field: Despite the substantial success realized treating osteosarcoma with chemotherapy, metastatic disease or refractory/recurrent disease continue to frustrate patients and clinicians. The failure to improve outcomes with treatment intensification indicates the need for new approaches, such as the introduction of targeted therapy. The application of trastuzumab (Herceptin®) in the setting of HER-2 positive osteosarcoma is reflective of this concept. Areas covered in this review: This review summarizes reports from 1996 to the present which focus on HER-2 expression and its prognostic relevance in the setting of osteosarcoma. What the reader will gain: The prognostic value of HER-2 remains controversial, and both standard methodologies for assessing expression and the effectiveness of HER-2 directed therapy in this patient population have yet to be established. Take home message: The relative rarity of the disease makes larger prospective studies difficult in terms of both time and coordination. The feasibility of defining therapy specifically for a subpopulation of patients afflicted with a rare cancer, such as osteosarcoma, can be conceptually questioned.

Original languageEnglish (US)
Pages (from-to)51-61
Number of pages11
JournalExpert Opinion on Pharmacotherapy
Volume11
Issue number1
DOIs
StatePublished - Jan 2010

Fingerprint

Osteosarcoma
Neoplasms
Therapeutics
Prospective Studies
Drug Therapy
Population
Trastuzumab

Keywords

  • HER-2
  • HER-2/ErbB2
  • Herceptin
  • Osteogenic sarcoma
  • Osteosarcoma
  • Trastuzumab

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology

Cite this

@article{0f375ee515fc4d04baa86476ff13461d,
title = "HER-2 targeted treatment of osteosarcoma: The challenges of developing targeted therapy and prognostic factors for rare malignancies",
abstract = "Importance of the field: Despite the substantial success realized treating osteosarcoma with chemotherapy, metastatic disease or refractory/recurrent disease continue to frustrate patients and clinicians. The failure to improve outcomes with treatment intensification indicates the need for new approaches, such as the introduction of targeted therapy. The application of trastuzumab (Herceptin{\circledR}) in the setting of HER-2 positive osteosarcoma is reflective of this concept. Areas covered in this review: This review summarizes reports from 1996 to the present which focus on HER-2 expression and its prognostic relevance in the setting of osteosarcoma. What the reader will gain: The prognostic value of HER-2 remains controversial, and both standard methodologies for assessing expression and the effectiveness of HER-2 directed therapy in this patient population have yet to be established. Take home message: The relative rarity of the disease makes larger prospective studies difficult in terms of both time and coordination. The feasibility of defining therapy specifically for a subpopulation of patients afflicted with a rare cancer, such as osteosarcoma, can be conceptually questioned.",
keywords = "HER-2, HER-2/ErbB2, Herceptin, Osteogenic sarcoma, Osteosarcoma, Trastuzumab",
author = "Geller, {David S.} and Richard Gorlick",
year = "2010",
month = "1",
doi = "10.1517/14656560903419614",
language = "English (US)",
volume = "11",
pages = "51--61",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - HER-2 targeted treatment of osteosarcoma

T2 - The challenges of developing targeted therapy and prognostic factors for rare malignancies

AU - Geller, David S.

AU - Gorlick, Richard

PY - 2010/1

Y1 - 2010/1

N2 - Importance of the field: Despite the substantial success realized treating osteosarcoma with chemotherapy, metastatic disease or refractory/recurrent disease continue to frustrate patients and clinicians. The failure to improve outcomes with treatment intensification indicates the need for new approaches, such as the introduction of targeted therapy. The application of trastuzumab (Herceptin®) in the setting of HER-2 positive osteosarcoma is reflective of this concept. Areas covered in this review: This review summarizes reports from 1996 to the present which focus on HER-2 expression and its prognostic relevance in the setting of osteosarcoma. What the reader will gain: The prognostic value of HER-2 remains controversial, and both standard methodologies for assessing expression and the effectiveness of HER-2 directed therapy in this patient population have yet to be established. Take home message: The relative rarity of the disease makes larger prospective studies difficult in terms of both time and coordination. The feasibility of defining therapy specifically for a subpopulation of patients afflicted with a rare cancer, such as osteosarcoma, can be conceptually questioned.

AB - Importance of the field: Despite the substantial success realized treating osteosarcoma with chemotherapy, metastatic disease or refractory/recurrent disease continue to frustrate patients and clinicians. The failure to improve outcomes with treatment intensification indicates the need for new approaches, such as the introduction of targeted therapy. The application of trastuzumab (Herceptin®) in the setting of HER-2 positive osteosarcoma is reflective of this concept. Areas covered in this review: This review summarizes reports from 1996 to the present which focus on HER-2 expression and its prognostic relevance in the setting of osteosarcoma. What the reader will gain: The prognostic value of HER-2 remains controversial, and both standard methodologies for assessing expression and the effectiveness of HER-2 directed therapy in this patient population have yet to be established. Take home message: The relative rarity of the disease makes larger prospective studies difficult in terms of both time and coordination. The feasibility of defining therapy specifically for a subpopulation of patients afflicted with a rare cancer, such as osteosarcoma, can be conceptually questioned.

KW - HER-2

KW - HER-2/ErbB2

KW - Herceptin

KW - Osteogenic sarcoma

KW - Osteosarcoma

KW - Trastuzumab

UR - http://www.scopus.com/inward/record.url?scp=72849133542&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=72849133542&partnerID=8YFLogxK

U2 - 10.1517/14656560903419614

DO - 10.1517/14656560903419614

M3 - Article

C2 - 20001429

AN - SCOPUS:72849133542

VL - 11

SP - 51

EP - 61

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 1

ER -